Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis

Hamberg, Viggo ; Wallman, Johan K. LU ; Mogard, Elisabeth LU orcid ; Lindqvist, Elisabet LU orcid ; Olofsson, Tor LU and Andréasson, Kristofer LU (2023) In Rheumatology International 43(5). p.961-967
Abstract

Knowledge on gastrointestinal manifestations in early systemic sclerosis (SSc) is limited. We have investigated gastrointestinal inflammation in SSc at the time of diagnosis using the inflammatory biomarker Fecal calprotectin (F-cal). Consecutive patients with suspected SSc were characterized in relation to the 2013 classification criteria for SSc and classified as SSc or SSc-like disease. F-cal levels were measured with a polyclonal ELISA (Calpro A/S, Lysaker, Norway) and levels above 50 µg/g were considered elevated. F-cal levels were compared to those of control subjects without rheumatic disease. Of 137 patients with suspected SSc, 92 were classified as SSc and 45 as SSc-like disease. Median (interquartile range) disease duration... (More)

Knowledge on gastrointestinal manifestations in early systemic sclerosis (SSc) is limited. We have investigated gastrointestinal inflammation in SSc at the time of diagnosis using the inflammatory biomarker Fecal calprotectin (F-cal). Consecutive patients with suspected SSc were characterized in relation to the 2013 classification criteria for SSc and classified as SSc or SSc-like disease. F-cal levels were measured with a polyclonal ELISA (Calpro A/S, Lysaker, Norway) and levels above 50 µg/g were considered elevated. F-cal levels were compared to those of control subjects without rheumatic disease. Of 137 patients with suspected SSc, 92 were classified as SSc and 45 as SSc-like disease. Median (interquartile range) disease duration among the SSc participants was 2.5 (1.2, 4.6) years. A substantial proportion of participants classified as SSc (35/92, 38%) and SSc-like disease (14/45, 31%) exhibited elevated F-cal compared to the control group (3/41, 7.3%; p < 0.001 and p = 0.007, respectively). Elevated F-cal was associated with proton pump inhibitor usage (OR 7.14; 95% CI 2.56–29.93; p < 0.001). We conclude that elevated F-cal is present in a subgroup of patients with SSc at the time of diagnosis, suggesting that that GI inflammation may be present in this patient group early in the disease course. F-cal did not exhibit potential to differentiate SSc from SSc-like disease.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Biomarker, Gastrointestinal, Inflammation, Systemic sclerosis
in
Rheumatology International
volume
43
issue
5
pages
7 pages
publisher
Springer
external identifiers
  • scopus:85144884312
  • pmid:36566433
ISSN
0172-8172
DOI
10.1007/s00296-022-05264-4
language
English
LU publication?
yes
id
0ca737c0-a8bf-4166-9aaf-5047b2006f96
date added to LUP
2023-01-23 12:16:55
date last changed
2024-06-25 19:43:12
@article{0ca737c0-a8bf-4166-9aaf-5047b2006f96,
  abstract     = {{<p>Knowledge on gastrointestinal manifestations in early systemic sclerosis (SSc) is limited. We have investigated gastrointestinal inflammation in SSc at the time of diagnosis using the inflammatory biomarker Fecal calprotectin (F-cal). Consecutive patients with suspected SSc were characterized in relation to the 2013 classification criteria for SSc and classified as SSc or SSc-like disease. F-cal levels were measured with a polyclonal ELISA (Calpro A/S, Lysaker, Norway) and levels above 50 µg/g were considered elevated. F-cal levels were compared to those of control subjects without rheumatic disease. Of 137 patients with suspected SSc, 92 were classified as SSc and 45 as SSc-like disease. Median (interquartile range) disease duration among the SSc participants was 2.5 (1.2, 4.6) years. A substantial proportion of participants classified as SSc (35/92, 38%) and SSc-like disease (14/45, 31%) exhibited elevated F-cal compared to the control group (3/41, 7.3%; p &lt; 0.001 and p = 0.007, respectively). Elevated F-cal was associated with proton pump inhibitor usage (OR 7.14; 95% CI 2.56–29.93; p &lt; 0.001). We conclude that elevated F-cal is present in a subgroup of patients with SSc at the time of diagnosis, suggesting that that GI inflammation may be present in this patient group early in the disease course. F-cal did not exhibit potential to differentiate SSc from SSc-like disease.</p>}},
  author       = {{Hamberg, Viggo and Wallman, Johan K. and Mogard, Elisabeth and Lindqvist, Elisabet and Olofsson, Tor and Andréasson, Kristofer}},
  issn         = {{0172-8172}},
  keywords     = {{Biomarker; Gastrointestinal; Inflammation; Systemic sclerosis}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{961--967}},
  publisher    = {{Springer}},
  series       = {{Rheumatology International}},
  title        = {{Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis}},
  url          = {{http://dx.doi.org/10.1007/s00296-022-05264-4}},
  doi          = {{10.1007/s00296-022-05264-4}},
  volume       = {{43}},
  year         = {{2023}},
}